Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion

Cardiac adverse effects are among the leading causes of the discontinuation of clinical trials and the withdrawal of drugs from the market. The novel concept of ‘hidden cardiotoxicity’ is defined as cardiotoxicity of a drug that manifests in the diseased (e.g. ischemic/reperfused), but n...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Gábor B. Brenner, András Makkos, Csilla Terézia Nagy, Zsófia Onódi, Nabil V. Sayour, Tamás G. Gergely, Bernadett Kiss, Anikó Görbe, Éva Sághy, Zoltán S. Zádori, Bernadette Lázár, Tamás Baranyai, Richárd S. Varga, Zoltán Husti, András Varró, László Tóthfalusi, Rainer Schulz, István Baczkó, Zoltán Giricz, Péter Ferdinandy
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2020-02-01
Edice:	Cells
Témata:	cardiotoxicity cox-2 electrophysiology safety testing arrhythmia vioxx ischemic conditioning reperfusion injury hiddentox pharmacovigilance
On-line přístup:	https://www.mdpi.com/2073-4409/9/3/551
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!